Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1419220

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1419220

Europe Acute Myeloid Leukemia Diagnostics Market - Industry Trends and Forecast to 2033

PUBLISHED:
PAGES: 265 Pages
DELIVERY TIME: Inquiry
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 3500
PDF (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

Description

Table of Contents

List of Tables

Europe acute myeloid leukemia diagnostics market is projected to register a substantial CAGR of 10.8% in the forecast period of 2024 to 2031. The new market report contains data for the historic year 2022, the base year of calculation is 2023, and the forecast period is 2024 to 2031.

Market Segmentation

EUROPE Acute Myeloid Leukemia Diagnostics Market, By Product Type (Instruments, and Consumables & Accessories), Test Type (Imaging Test, Blood Test, Bone Marrow Test, Biomarker Test, Immunophenotyping, Genetic Testing and Others), Cancer Type (Myeloblastic (M0), Myeloblastic (M1), Myeloblastic (M2), Promyelocytic (M3), Myelomonocytic (M4), MONOCYTIC (M5), Erythroleukemia (M6) and Megakaryocytic (M7)), Age Group (Below 21, 21-29, 30-65, 65 and Above), Gender (Male and Female) End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales) Country, ( Europe, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, and Rest of Europe) - Industry Trends and Forecast to 2031.

Driver

Increasing diagnostic products for leukemia cancer

Restraint

Late diagnosis and Poor prognosis of leukemia

Opportunity

Initiatives by government and other authorities for life sciences and funding

Market Players

Some of the major market players in Europe acute myeloid leukemia diagnostics market are:

  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific, Inc.
  • QIAGEN
  • Abbott
  • Siemens Healthcare GmbH
  • Hologic, Inc.
  • Agilent Technologies, Inc.
  • DiaSorin S.p.A.
  • Illumina, Inc.
  • BIOMERIEUX
  • Myriad Genetics, Inc.
  • Quest Diagnostics Incorporated.
  • Bio-Rad Laboratories, Inc.
  • Koninklijke Philips N.V.
  • BD
  • Exact Sciences Corporation
  • Time Medical Holding
  • PlexBio
  • MinFound Medical Systems Co., Ltd
  • Medonica Co. LTD
  • CANON MEDICAL SYSTEMS CORPORATION
Show more

TABLE OF CONTENTS

1 INTRODUCTION 52

  • 1.1 OBJECTIVES OF THE STUDY 52
  • 1.2 MARKET DEFINITION 52
  • 1.3 OVERVIEW OF THE EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET 52
  • 1.4 LIMITATIONS 54
  • 1.5 MARKETS COVERED 55

2 MARKET SEGMENTATION 58

  • 2.1 MARKETS COVERED 58
  • 2.2 GEOGRAPHICAL SCOPE 59
  • 2.3 YEARS CONSIDERED FOR THE STUDY 60
  • 2.4 CURRENCY AND PRICING 60
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 61
  • 2.6 MULTIVARIATE MODELLING 64
  • 2.7 PRODUCT TYPE LIFELINE CURVE 64
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 65
  • 2.9 DBMR MARKET POSITION GRID 66
  • 2.10 MARKET END USER COVERAGE GRID 67
  • 2.11 VENDOR SHARE ANALYSIS 68
  • 2.12 SECONDARY SOURCES 69
  • 2.13 ASSUMPTIONS 69

3 EXECUTIVE SUMMARY 70

4 PREMIUM INSIGHTS 73

  • 4.1 PESTEL ANALYSIS 74
  • 4.2 PORTER'S FIVE FORCES 75
  • 4.3 EPIDEMIOLOGY 76

5 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, REGULATIONS 77

  • 5.1 REGULATORY SCENARIO IN THE U.S. 77
  • 5.2 REGULATORY SCENARIO IN AUSTRALIA 78
  • 5.3 REGULATORY SCENARIO IN JAPAN 78
  • 5.4 REGULATORY SCENARIO IN CHINA 78

 

6 MARKET OVERVIEW 80

  • 6.1 DRIVERS 82
    • 6.1.1 GROWING PREVALENCE OF LEUKEMIA CANCER 82
    • 6.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS 84
    • 6.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 84
    • 6.1.4 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER 85
  • 6.2 RESTRAINTS 85
    • 6.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS 85
    • 6.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA 86
  • 6.3 OPPORTUNITIES 86
    • 6.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA 86
    • 6.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 87
    • 6.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 88
  • 6.4 CHALLENGES 88
    • 6.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 88
    • 6.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 89

7 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE 90

  • 7.1 OVERVIEW 91
  • 7.2 INSTRUMENTS 94
    • 7.2.1 BIOPSY INSTRUMENTS 95
      • 7.2.1.1 BONE MARROW BIOPSY 95
      • 7.2.1.2 NEEDLE BIOPSY 95
      • 7.2.1.3 SURGICAL BIOPSY 95
      • 7.2.1.4 OTHERS 95
    • 7.2.2 PATHOLOGY-BASED INSTRUMENTS 96
      • 7.2.2.1 PCR INSTRUMENTS 96
      • 7.2.2.2 SLIDE STAINING SYSTEMS 96
      • 7.2.2.3 TISSUE PROCESSING SYSTEMS 96
      • 7.2.2.4 CELL PROCESSORS 96
      • 7.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS 96
    • 7.2.3 IMAGING INSTRUMENTS 97
      • 7.2.3.1 ULTRASOUND SYSTEMS 97
      • 7.2.3.2 CT SYSTEMS 97
      • 7.2.3.3 MRI SYSTEMS 97
      • 7.2.3.4 OTHERS 97
    • 7.2.4 OTHERS 97

 

  • 7.3 CONSUMABLES & ACCESSORIES 98
    • 7.3.1 KITS 99
      • 7.3.1.1 PCR KITS 99
      • 7.3.1.2 DNA POLYMERASE KITS 99
      • 7.3.1.3 NUCLEIC ACID ISOLATION KITS 99
      • 7.3.1.4 OTHERS 99
    • 7.3.2 REAGENTS 100
      • 7.3.2.1 ASSAYS 100
      • 7.3.2.2 BUFFERS 100
      • 7.3.2.3 PRIMERS 100
      • 7.3.2.4 OTHERS 100
    • 7.3.3 PROBES 101
    • 7.3.4 OTHER CONSUMABLES 101

8 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE 102

  • 8.1 OVERVIEW 103
  • 8.2 BLOOD TEST 106
    • 8.2.1 COMPLETE BLOOD COUNT (CBC) 107
    • 8.2.2 BLOOD CHEMISTRY TESTS 107
    • 8.2.3 OTHERS 107
  • 8.3 IMAGING TEST 108
    • 8.3.1 COMPUTED TOMOGRAPHY (CT) SCAN 108
    • 8.3.2 MRI 108
    • 8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 109
    • 8.3.4 OTHERS 109
  • 8.4 BONE MARROW TESTS 109
    • 8.4.1 BONE MARROW ASPIRATE 110
    • 8.4.2 BONE MARROW BIOPSY 110
    • 8.4.3 OTHERS 110
  • 8.5 GENETIC TESTS 110
    • 8.5.1 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 111
    • 8.5.2 KARYOTYPING 111
    • 8.5.3 OTHERS 111
  • 8.6 BIOMARKER TEST 112
    • 8.6.1 GENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 112
    • 8.6.2 EPIGENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 112
    • 8.6.3 PROTEOMIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 113

 

  • 8.7 IMMUNOPHENOTYPING 113
    • 8.7.1 FLOW CYTOMETRY 113
    • 8.7.2 IMMUNOHISTOCHEMISTRY 114
    • 8.7.3 OTHERS 114
  • 8.8 OTHERS 114

9 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE 115

  • 9.1 OVERVIEW 116
  • 9.2 MYELOBLASTIC (M0) 119
  • 9.3 MYELOBLASTIC (M1) 120
  • 9.4 MYELOBLASTIC (M2) 120
  • 9.5 PROMYELOCYTIC (M3) 121
  • 9.6 MYELOMONOCYTIC (M4) 121
  • 9.7 MONOCYTIC (M5) 122
  • 9.8 ERYTHROLEUKEMIA (M6) 122
  • 9.9 MEGAKARYOCYTIC (M7) 123

10 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP 124

  • 10.1 OVERVIEW 125
  • 10.2 65 AND ABOVE 128
  • 10.3 30-65 129
  • 10.4 BELOW 21 129
  • 10.5 21-29 130

11 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER 131

  • 11.1 OVERVIEW 132
  • 11.2 MALE 135
  • 11.3 FEMALE 136

12 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER 137

  • 12.1 OVERVIEW 138
  • 12.2 HOSPITALS 141
  • 12.3 ASSOCIATED LABS 142
  • 12.4 INDEPENDENT DIAGNOSTIC LABORATORIES 142
  • 12.5 DIAGNOSTIC IMAGING CENTERS 143
  • 12.6 CANCER RESEARCH INSTITUTES 143
  • 12.7 OTHERS 144

 

13 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 145

  • 13.1 OVERVIEW 146
  • 13.2 DIRECT TENDER 149
  • 13.3 RETAIL SALES 150

14 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION 151

  • 14.1 EUROPE 154
    • 14.1.1 GERMANY 160
    • 14.1.2 UNITED KINGDOM 165
    • 14.1.3 FRANCE 170
    • 14.1.4 ITALY 175
    • 14.1.5 SPAIN 180
    • 14.1.6 RUSSIA 185
    • 14.1.7 NETHERLANDS 190
    • 14.1.8 SWITZERLAND 195
    • 14.1.9 BELGIUM 200
    • 14.1.10 TURKEY 205
    • 14.1.11 REST OF EUROPE 210

15 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 211

  • 15.1 COMPANY SHARE ANALYSIS: EUROPE

16 SWOT ANALYSIS 212

17 COMPANY PROFILES 213

  • 17.1 CANON MEDICAL SYSTEMS CORPORATION. 213
    • 17.1.1 COMPANY SNAPSHOT 213
    • 17.1.2 REVENUE ANALYSIS 214
    • 17.1.3 COMPANY SHARE ANALYSIS 214
    • 17.1.4 PRODUCT PORTFOLIO 215
    • 17.1.5 RECENT DEVELOPMENT 215
  • 17.2 SYSMEX CORPORATION 216
    • 17.2.1 COMPANY SNAPSHOT 216
    • 17.2.2 REVENUE ANALYSIS 216
    • 17.2.3 COMPANY SHARE ANALYSIS 217
    • 17.2.4 PRODUCT PORTFOLIO 217
    • 17.2.5 RECENT DEVELOPMENT 217

 

  • 17.3 EPIGENOMICS AG. 218
    • 17.3.1 COMPANY SNAPSHOT 218
    • 17.3.2 REVENUE ANALYSIS 218
    • 17.3.3 COMPANY SHARE ANALYSIS 219
    • 17.3.4 PRODUCT PORTFOLIO 219
    • 17.3.5 RECENT DEVELOPMENT 220
  • 17.4 MYRIAD GENETICS, INC. 221
    • 17.4.1 COMPANY SNAPSHOT 221
    • 17.4.2 REVENUE ANALYSIS 221
    • 17.4.3 COMPANY SHARE ANALYSIS 222
    • 17.4.4 PRODUCT PORTFOLIO 222
    • 17.4.5 RECENT DEVELOPMENT 223
  • 17.5 F. HOFFMANN- LA ROCHE LTD 224
    • 17.5.1 COMPANY SNAPSHOT 224
    • 17.5.2 REVENUE ANALYSIS 224
    • 17.5.3 COMPANY SHARE ANALYSIS 225
    • 17.5.4 PRODUCT PORTFOLIO 225
    • 17.5.5 RECENT DEVELOPMENT 225
  • 17.6 ABBOTT 226
    • 17.6.1 COMPANY SNAPSHOT 226
    • 17.6.2 REVENUE ANALYSIS 226
    • 17.6.3 PRODUCT PORTFOLIO 227
    • 17.6.4 RECENT DEVELOPMENT 227
  • 17.7 AGILENT TECHNOLOGIES, INC. 228
    • 17.7.1 COMPANY SNAPSHOT 228
    • 17.7.2 REVENUE ANALYSIS 228
    • 17.7.3 PRODUCT PORTFOLIO 229
    • 17.7.4 RECENT DEVELOPMENT 229
  • 17.8 BD 230
    • 17.8.1 COMPANY SNAPSHOT 230
    • 17.8.2 REVENUE ANALYSIS 230
    • 17.8.3 PRODUCT PORTFOLIO 231
    • 17.8.4 RECENT DEVELOPMENT 231
  • 17.9 BIOMERIEUX 232
    • 17.9.1 COMPANY SNAPSHOT 232
    • 17.9.2 PRODUCT PORTFOLIO 232
    • 17.9.3 RECENT DEVELOPMENT 232

 

  • 17.10 BIO-RAD LABORATORIES, INC. 233
    • 17.10.1 COMPANY SNAPSHOT 233
    • 17.10.2 REVENUE ANALYSIS 233
    • 17.10.3 PRODUCT PORTFOLIO 234
    • 17.10.4 RECENT DEVELOPMENT 234
  • 17.11 DIASORIN S.P.A. 235
    • 17.11.1 COMPANY SNAPSHOT 235
    • 17.11.2 REVENUE ANALYSIS 235
    • 17.11.3 PRODUCT PORTFOLIO 236
    • 17.11.4 RECENT DEVELOPMENTS 236
  • 17.12 EXACT SCIENCES CORPORATION 237
    • 17.12.1 COMPANY SNAPSHOT 237
    • 17.12.2 REVENUE ANALYSIS 237
    • 17.12.3 PRODUCT PORTFOLIO 238
    • 17.12.4 RECENT DEVELOPMENTS 238
  • 17.13 HOLOGIC INC. 239
    • 17.13.1 COMPANY SNAPSHOT 239
    • 17.13.2 REVENUE ANALYSIS 239
    • 17.13.3 PRODUCT PORTFOLIO 240
    • 17.13.4 RECENT DEVELOPMENT 240
  • 17.14 ILLUMINA, INC. 241
    • 17.14.1 COMPANY SNAPSHOT 241
    • 17.14.2 REVENUE ANALYSIS 241
    • 17.14.3 PRODUCT PORTFOLIO 242
    • 17.14.4 RECENT DEVELOPMENT 242
  • 17.15 KONINKLIJKE PHILIPS N.V. 243
    • 17.15.1 COMPANY SNAPSHOT 243
    • 17.15.2 REVENUE ANALYSIS 243
    • 17.15.3 PRODUCT PORTFOLIO 244
    • 17.15.4 RECENT DEVELOPMENT 244
  • 17.16 MEDONICA CO. LTD 245
    • 17.16.1 COMPANY SNAPSHOT 245
    • 17.16.2 PRODUCT PORTFOLIO 245
    • 17.16.3 RECENT DEVELOPMENT 245
  • 17.17 MINFOUND MEDICAL SYSTEMS CO., LTD 246
    • 17.17.1 COMPANY SNAPSHOT 246
    • 17.17.2 PRODUCT PORTFOLIO 246
    • 17.17.3 RECENT DEVELOPMENT 247

 

  • 17.18 PLEXBIO 248
    • 17.18.1 COMPANY SNAPSHOT 248
    • 17.18.2 PRODUCT PORTFOLIO 248
    • 17.18.3 RECENT DEVELOPMENTS 248
  • 17.19 QIAGEN 249
    • 17.19.1 COMPANY SNAPSHOT 249
    • 17.19.2 REVENUE ANALYSIS 249
    • 17.19.3 PRODUCT PORTFOLIO 250
    • 17.19.4 RECENT DEVELOPMENTS 250
  • 17.20 QUEST DIAGNOSTICS INCORPORATED 251
    • 17.20.1 COMPANY SNAPSHOT 251
    • 17.20.2 REVENUE ANALYSIS 251
    • 17.20.3 PRODUCT PORTFOLIO 252
    • 17.20.4 RECENT DEVELOPMENTS 252
  • 17.21 SIEMENS HEALTHCARE GMBH 253
    • 17.21.1 COMPANY SNAPSHOT 253
    • 17.21.2 REVENUE ANALYSIS 253
    • 17.21.3 PRODUCT PORTFOLIO 254
    • 17.21.4 RECENT DEVELOPMENT 254
  • 17.22 SONIC HEALTHCARE 255
    • 17.22.1 COMPANY SNAPSHOT 255
    • 17.22.2 PRODUCT PORTFOLIO 255
    • 17.22.3 RECENT DEVELOPMENT 255
  • 17.23 STERNMED GMBH 256
    • 17.23.1 COMPANY SNAPSHOT 256
    • 17.23.2 PRODUCT PORTFOLIO 256
    • 17.23.3 RECENT DEVELOPMENTS 256
  • 17.24 THERMO FISHER SCIENTIFIC INC. 257
    • 17.24.1 COMPANY SNAPSHOT 257
    • 17.24.2 REVENUE ANALYSIS 257
    • 17.24.3 PRODUCT PORTFOLIO 258
    • 17.24.4 RECENT DEVELOPMENT 258
  • 17.25 TIME MEDICAL HOLDING 259
    • 17.25.1 COMPANY SNAPSHOT 259
    • 17.25.2 PRODUCT PORTFOLIO 259
    • 17.25.3 RECENT DEVELOPMENT 260

18 QUESTIONNAIRE 261

19 RELATED REPORTS 265

Show more

LIST OF TABLES

  • TABLE 1 APPROVED DIAGNOSTICS OF LEUKEMIA 63
  • TABLE 2 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 70
  • TABLE 3 EUROPE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 70
  • TABLE 4 EUROPE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 70
  • TABLE 5 EUROPE BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 71
  • TABLE 6 EUROPE PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 72
  • TABLE 7 EUROPE IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 73
  • TABLE 8 EUROPE CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 74
  • TABLE 9 EUROPE CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 74
  • TABLE 10 EUROPE KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 75
  • TABLE 11 EUROPE REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 76
  • TABLE 12 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 82
  • TABLE 13 EUROPE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 82
  • TABLE 14 EUROPE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 83
  • TABLE 15 EUROPE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 84
  • TABLE 16 EUROPE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 84
  • TABLE 17 EUROPE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 85
  • TABLE 18 EUROPE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 85
  • TABLE 19 EUROPE GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 86
  • TABLE 20 EUROPE GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 87
  • TABLE 21 EUROPE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 88
  • TABLE 22 EUROPE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 88
  • TABLE 23 EUROPE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 89
  • TABLE 24 EUROPE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 89
  • TABLE 25 EUROPE OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 90
  • TABLE 26 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 95
  • TABLE 27 EUROPE MYELOBLASTIC (M0) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 95
  • TABLE 28 EUROPE MYELOBLASTIC (M1) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 96
  • TABLE 29 EUROPE MYELOBLASTIC (M2) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 96
  • TABLE 30 EUROPE PROMYELOCYTIC (M3) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 97
  • TABLE 31 EUROPE MYELOMONOCYTIC (M4) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 97
  • TABLE 32 EUROPE MONOCYTIC (M5) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 98
  • TABLE 33 EUROPE ERYTHROLEUKEMIA (M6) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 98
  • TABLE 34 EUROPE MEGAKARYOCYTIC (M7) ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 99
  • TABLE 35 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 104
  • TABLE 36 EUROPE 65 AND ABOVE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 104
  • TABLE 37 EUROPE 30-65 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 105
  • TABLE 38 EUROPE BELOW 21 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 105
  • TABLE 39 EUROPE 21-29 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 106
  • TABLE 40 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 111
  • TABLE 41 EUROPE MALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 111
  • TABLE 42 EUROPE FEMALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 112
  • TABLE 43 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 117
  • TABLE 44 EUROPE HOSPITALS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 117
  • TABLE 45 EUROPE ASSOCIATED LABS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 118
  • TABLE 46 EUROPE INDEPENDENT DIAGNOSTIC LABORATORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 118
  • TABLE 47 EUROPE DIAGNOSTIC IMAGING CENTERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 119
  • TABLE 48 EUROPE CANCER RESEARCH INSTITUTES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 119
  • TABLE 49 EUROPE OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 120
  • TABLE 50 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 125
  • TABLE 51 EUROPE DIRECT TENDER IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 125
  • TABLE 52 EUROPE RETAIL SALES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 126
  • TABLE 53 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 130
  • TABLE 54 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 130
  • TABLE 55 EUROPE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 130
  • TABLE 56 EUROPE BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 131
  • TABLE 57 EUROPE PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 131
  • TABLE 58 EUROPE IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 131
  • TABLE 59 EUROPE CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 131
  • TABLE 60 EUROPE KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 132
  • TABLE 61 EUROPE REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 132
  • TABLE 62 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 132
  • TABLE 63 EUROPE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 132
  • TABLE 64 EUROPE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 133
  • TABLE 65 EUROPE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 133
  • TABLE 66 EUROPE GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 133
  • TABLE 67 EUROPE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 133
  • TABLE 68 EUROPE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 134
  • TABLE 69 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 134
  • TABLE 70 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 134
  • TABLE 71 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 134
  • TABLE 72 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 135
  • TABLE 73 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 135
  • TABLE 74 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 136
  • TABLE 75 GERMANY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 136
  • TABLE 76 GERMANY BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 136
  • TABLE 77 GERMANY PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 136
  • TABLE 78 GERMANY IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 137
  • TABLE 79 GERMANY CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 137
  • TABLE 80 GERMANY KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 137
  • TABLE 81 GERMANY REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 137
  • TABLE 82 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 138
  • TABLE 83 GERMANY BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 138
  • TABLE 84 GERMANY IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 138
  • TABLE 85 GERMANY BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 138
  • TABLE 86 GERMANY GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 139
  • TABLE 87 GERMANY BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 139
  • TABLE 88 GERMANY IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 139
  • TABLE 89 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 139
  • TABLE 90 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 140
  • TABLE 91 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 140
  • TABLE 92 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 140
  • TABLE 93 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 140
  • TABLE 94 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 141
  • TABLE 95 UNITED KINGDOM INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 141
  • TABLE 96 UNITED KINGDOM BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 141
  • TABLE 97 UNITED KINGDOM PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 141
  • TABLE 98 UNITED KINGDOM IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 142
  • TABLE 99 UNITED KINGDOM CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 142
  • TABLE 100 UNITED KINGDOM KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 142
  • TABLE 101 UNITED KINGDOM REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 142
  • TABLE 102 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 143
  • TABLE 103 UNITED KINGDOM BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 143
  • TABLE 104 UNITED KINGDOM IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 143
  • TABLE 105 UNITED KINGDOM BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 143
  • TABLE 106 UNITED KINGDOM GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 144
  • TABLE 107 UNITED KINGDOM BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 144
  • TABLE 108 UNITED KINGDOM IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 144
  • TABLE 109 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 144
  • TABLE 110 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 145
  • TABLE 111 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 145
  • TABLE 112 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 145
  • TABLE 113 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 145
  • TABLE 114 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 146
  • TABLE 115 FRANCE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 146
  • TABLE 116 FRANCE BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 146
  • TABLE 117 FRANCE PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 146
  • TABLE 118 FRANCE IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 147
  • TABLE 119 FRANCE CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 147
  • TABLE 120 FRANCE KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 147
  • TABLE 121 FRANCE REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 147
  • TABLE 122 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 148
  • TABLE 123 FRANCE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 148
  • TABLE 124 FRANCE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 148
  • TABLE 125 FRANCE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 148
  • TABLE 126 FRANCE GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 149
  • TABLE 127 FRANCE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 149
  • TABLE 128 FRANCE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 149
  • TABLE 129 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 149
  • TABLE 130 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 150
  • TABLE 131 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 150
  • TABLE 132 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 150
  • TABLE 133 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 150
  • TABLE 134 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 151
  • TABLE 135 ITALY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 151
  • TABLE 136 ITALY BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 151
  • TABLE 137 ITALY PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 151
  • TABLE 138 ITALY IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 152
  • TABLE 139 ITALY CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 152
  • TABLE 140 ITALY KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 152
  • TABLE 141 ITALY REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 152
  • TABLE 142 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 153
  • TABLE 143 ITALY BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 153
  • TABLE 144 ITALY IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 153
  • TABLE 145 ITALY BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 153
  • TABLE 146 ITALY GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 154
  • TABLE 147 ITALY BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 154
  • TABLE 148 ITALY IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 154
  • TABLE 149 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 154
  • TABLE 150 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 155
  • TABLE 151 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 155
  • TABLE 152 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 155
  • TABLE 153 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 155
  • TABLE 154 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 156
  • TABLE 155 SPAIN INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 156
  • TABLE 156 SPAIN BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 156
  • TABLE 157 SPAIN PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 156
  • TABLE 158 SPAIN IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 157
  • TABLE 159 SPAIN CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 157
  • TABLE 160 SPAIN KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 157
  • TABLE 161 SPAIN REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 157
  • TABLE 162 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 158
  • TABLE 163 SPAIN BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 158
  • TABLE 164 SPAIN IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 158
  • TABLE 165 SPAIN BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 158
  • TABLE 166 SPAIN GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 159
  • TABLE 167 SPAIN BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 159
  • TABLE 168 SPAIN IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 159
  • TABLE 169 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 159
  • TABLE 170 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 160
  • TABLE 171 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 160
  • TABLE 172 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 160
  • TABLE 173 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 160
  • TABLE 174 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 161
  • TABLE 175 RUSSIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 161
  • TABLE 176 RUSSIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 161
  • TABLE 177 RUSSIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 161
  • TABLE 178 RUSSIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 162
  • TABLE 179 RUSSIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 162
  • TABLE 180 RUSSIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 162
  • TABLE 181 RUSSIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 162
  • TABLE 182 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 163
  • TABLE 183 RUSSIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 163
  • TABLE 184 RUSSIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 163
  • TABLE 185 RUSSIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 163
  • TABLE 186 RUSSIA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 164
  • TABLE 187 RUSSIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 164
  • TABLE 188 RUSSIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 164
  • TABLE 189 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 164
  • TABLE 190 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 165
  • TABLE 191 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 165
  • TABLE 192 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 165
  • TABLE 193 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 165
  • TABLE 194 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 166
  • TABLE 195 NETHERLANDS INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 166
  • TABLE 196 NETHERLANDS BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 166
  • TABLE 197 NETHERLANDS PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 166
  • TABLE 198 NETHERLANDS IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 167
  • TABLE 199 NETHERLANDS CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 167
  • TABLE 200 NETHERLANDS KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 167
  • TABLE 201 NETHERLANDS REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 167
  • TABLE 202 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 168
  • TABLE 203 NETHERLANDS BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 168
  • TABLE 204 NETHERLANDS IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 168
  • TABLE 205 NETHERLANDS BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 168
  • TABLE 206 NETHERLANDS GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 169
  • TABLE 207 NETHERLANDS BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 169
  • TABLE 208 NETHERLANDS IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 169
  • TABLE 209 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 169
  • TABLE 210 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 170
  • TABLE 211 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 170
  • TABLE 212 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 170
  • TABLE 213 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 170
  • TABLE 214 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 171
  • TABLE 215 SWITZERLAND INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 171
  • TABLE 216 SWITZERLAND BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 171
  • TABLE 217 SWITZERLAND PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 171
  • TABLE 218 SWITZERLAND IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 172
  • TABLE 219 SWITZERLAND CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 172
  • TABLE 220 SWITZERLAND KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 172
  • TABLE 221 SWITZERLAND REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 172
  • TABLE 222 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 173
  • TABLE 223 SWITZERLAND BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 173
  • TABLE 224 SWITZERLAND IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 173
  • TABLE 225 SWITZERLAND BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 173
  • TABLE 226 SWITZERLAND GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 174
  • TABLE 227 SWITZERLAND BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 174
  • TABLE 228 SWITZERLAND IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 174
  • TABLE 229 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 174
  • TABLE 230 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 175
  • TABLE 231 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 175
  • TABLE 232 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 175
  • TABLE 233 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 175
  • TABLE 234 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 176
  • TABLE 235 BELGIUM INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 176
  • TABLE 236 BELGIUM BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 176
  • TABLE 237 BELGIUM PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 176
  • TABLE 238 BELGIUM IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 177
  • TABLE 239 BELGIUM CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 177

LIST OF FIGURES

  • FIGURE 1 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SEGMENTATION 34
  • FIGURE 2 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: DATA TRIANGULATION 37
  • FIGURE 3 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: DROC ANALYSIS 38
  • FIGURE 4 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 39
  • FIGURE 5 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 39
  • FIGURE 6 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 41
  • FIGURE 7 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DBMR MARKET POSITION GRID 42
  • FIGURE 8 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID 43
  • FIGURE 9 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 44
  • FIGURE 10 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SEGMENTATION 48
  • FIGURE 11 THE GROWING PREVALENCE OF LEUKEMIA CANCER IS EXPECTED TO DRIVE THE EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN THE FORECAST PERIOD 49
  • FIGURE 12 THE INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN 2024 & 2031 49
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET 57
  • FIGURE 14 NUMBER OF PREVALENCE OF LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES) 59
  • FIGURE 15 FIVE YEARS PREVALENCE LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES) 59
  • FIGURE 16 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023 67
  • FIGURE 17 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2024-2031 (USD MILLION) 68
  • FIGURE 18 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2024-2031) 68
  • FIGURE 19 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 69
  • FIGURE 20 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2023 79
  • FIGURE 21 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2024-2031 (USD MILLION) 80
  • FIGURE 22 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2024-2031) 80
  • FIGURE 23 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 81
  • FIGURE 24 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2023 92
  • FIGURE 25 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2024-2031 (USD MILLION) 93
  • FIGURE 26 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2024-2031) 93
  • FIGURE 27 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 94
  • FIGURE 28 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2023 101
  • FIGURE 29 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2024-2031 (USD MILLION) 102
  • FIGURE 30 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2024-2031) 102
  • FIGURE 31 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE 103
  • FIGURE 32 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2023 108
  • FIGURE 33 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2024-2031 (USD MILLION) 109
  • FIGURE 34 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, CAGR (2024-2031) 109
  • FIGURE 35 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE 110
  • FIGURE 36 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2023 114
  • FIGURE 37 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2024-2031 (USD MILLION) 115
  • FIGURE 38 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, CAGR (2024-2031) 115
  • FIGURE 39 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 116
  • FIGURE 40 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023 122
  • FIGURE 41 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION) 123
  • FIGURE 42 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 123
  • FIGURE 43 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 124
  • FIGURE 44 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SNAPSHOT (2023) 128
  • FIGURE 45 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY SHARE 2023(%) 187

 

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!